Mifepristone (50 mg/1 day after/3 months) may leads to higher cystic glandular dilatationdichotomic compared with placebo (low certainty).
Controlled‐release mesalamine (1 ‐ 2 g/day) showed no clear difference in decrease in CDAI >=50, HBI >=2 or improvement/remission (as defined… compared with placebo (low certainty).
Controlled‐release mesalamine (1 ‐ 2 g/day) showed no clear difference in induction of remission (CDAI <=150 + decrease of >=50 or as defined… compared with placebo (low certainty).
It is very uncertain whether early and late (day 1 to 28 after birth) higher changes hypernatraemia (≥ 150 mmol/L) compared with lower sodium intake (very low certainty).
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher leaving the study early: any reason ‐ when compared with high dose (… compared with ANY DOSE ‐ short term (moderate certainty).
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to lower adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).
Late (seven days or more following birth) higher may leads to lower hyponatraemia (< 130 mmol/L) compared with lower sodium intake (low certainty).
It is very uncertain whether late (seven days or more following birth) higher changes hypernatraemia (≥ 150 mmol/L) compared with lower sodium intake (very low certainty).
Late (seven days or more following birth) higher may leads to lower postnatal growth failure (weight < 10th percentile) compared with lower sodium intake (low certainty).
It is very uncertain whether late (seven days or more following birth) higher changes necrotising enterocolitis compared with lower sodium intake (very low certainty).
It is very uncertain whether late (seven days or more following birth) higher changes chronic lung disease compared with lower sodium intake (very low certainty).
It is very uncertain whether late (seven days or more following birth) higher changes mortality (latest time reported up to hospital discharge) compared with lower sodium intake (very low certainty).
It is very uncertain whether benzodiazepines (systemic clonazepam 0.5 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).